These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37015943)

  • 1. Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer.
    Gahlawat AW; Witte T; Sinn P; Schott S
    Sci Rep; 2023 Apr; 13(1):5503. PubMed ID: 37015943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis.
    Gahlawat AW; Witte T; Haarhuis L; Schott S
    Br J Cancer; 2022 Nov; 127(8):1550-1556. PubMed ID: 35931806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
    Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
    EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
    Yu Z; Qin S; Wang H
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
    Balla A; Bhak J; Biró O
    Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer.
    Aboutalebi H; Bahrami A; Soleimani A; Saeedi N; Rahmani F; Khazaei M; Fiuji H; Shafiee M; Ferns GA; Avan A; Hassanian SM
    Int J Biochem Cell Biol; 2020 Jul; 124():105765. PubMed ID: 32428568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.
    Khandelwal A; Seam RK; Gupta M; Rana MK; Prakash H; Vasquez KM; Jain A
    Cancer Sci; 2020 Mar; 111(3):826-839. PubMed ID: 31520555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of circulating microRNAs as non-invasive biomarkers in the diagnosis of ovarian cancer: a case-control study.
    Berner K; Hirschfeld M; Weiß D; Rücker G; Asberger J; Ritter A; Nöthling C; Jäger M; Juhasz-Böss I; Erbes T
    Arch Gynecol Obstet; 2022 Jul; 306(1):151-163. PubMed ID: 34889994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating microRNAs for Early Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis.
    Frisk NLS; Sørensen AE; Pedersen OBV; Dalgaard LT
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
    Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
    Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
    Oliveira DNP; Carlsen AL; Heegaard NHH; Prahm KP; Christensen IJ; Høgdall CK; Høgdall EV
    PLoS One; 2019; 14(11):e0225249. PubMed ID: 31738788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
    Terp SK; Stoico MP; Dybkær K; Pedersen IS
    Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potential serum and urine-based microRNA as minimally-invasive biomarkers for breast and gynecological cancer.
    Ritter A; Hirschfeld M; Berner K; Jaeger M; Grundner-Culemann F; Schlosser P; Asberger J; Weiss D; Noethling C; Mayer S; Erbes T
    Cancer Biomark; 2020; 27(2):225-242. PubMed ID: 32083575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
    Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
    J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of circulating cell-free microRNAs in ovarian cancer.
    Nakamura K; Sawada K; Yoshimura A; Kinose Y; Nakatsuka E; Kimura T
    Mol Cancer; 2016 Jun; 15(1):48. PubMed ID: 27343009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer.
    Widschwendter M; Zikan M; Wahl B; Lempiäinen H; Paprotka T; Evans I; Jones A; Ghazali S; Reisel D; Eichner J; Rujan T; Yang Z; Teschendorff AE; Ryan A; Cibula D; Menon U; Wittenberger T
    Genome Med; 2017 Dec; 9(1):116. PubMed ID: 29268796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
    Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
    Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of ovarian cancer using plasma cell-free DNA methylomes.
    Lu H; Liu Y; Wang J; Fu S; Wang L; Huang C; Li J; Xie L; Wang D; Li D; Zhou H; Rao Q
    Clin Epigenetics; 2022 Jun; 14(1):74. PubMed ID: 35681212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can circulating cell free DNA be a promising marker in ovarian cancer? - a genome-scale profiling study in a single institution.
    Zhou H; Zhang X; Liu Q; Yang J; Bai J; Yin M; Cao D; Zhang Q; Zheng L
    J Ovarian Res; 2023 Jan; 16(1):11. PubMed ID: 36641505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.